4-t-Butyl-1,2-dihydro-1-methyl-2-oxo-pyrimidin | 17322-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-t-Butyl-1,2-dihydro-1-methyl-2-oxo-pyrimidin
• 英文别名: 4-tert-butyl-1-methyl-1H-pyrimidin-2-one；Pyrimidine, 4-t-butyl-1,2-dihydro-1-methyl-2-oxo-；4-tert-butyl-1-methylpyrimidin-2-one
• CAS: 17322-02-0
• 化学式: C₉H₁₄N₂O
• 分子量: 166.223
• InChiKey: FSSNXMRXDZNMPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Plexxikon Inc.

  公开号：US20160075712A1

  公开（公告）日：2016-03-17

  Heterocyclic compounds of formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses.

  式(I)的杂环化合物，含有这种化合物的制药组合物及其治疗用途。
• SULPHIDE BRIDGED DERIVATIVES AS MODULATORS OF MGLUR5 733
  申请人：Granberg Kenneth

  公开号：US20100273805A1

  公开（公告）日：2010-10-28

  The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

  本发明涉及新化合物、它们的制备方法、它们在治疗中的应用以及包含这些新化合物的药物组合物。
• IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：Lai Yingjie

  公开号：US20130096104A1

  公开（公告）日：2013-04-18

  The invention provides compounds of Formulas Ia-Ib, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R 1 , R 2 , R 4 , R 5 and R 16 are defined herein, a pharmaceutical composition that includes a compound of Formulas Ia-Ib and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy, as an inhibitor of TYK2 kinase and conditions related, such as inflammatory illnesses, inflammatory bowel disease or psoriasis.

  本发明提供了公式Ia-Ib的化合物、立体异构体或其药学上可接受的盐，其中A、X、R1、R2、R4、R5和R16在此定义，一种包括公式Ia-Ib化合物和药学上可接受的载体、佐剂或车载物的药物组合物，以及使用该化合物或组合物作为TYK2激酶的抑制剂和相关疾病的治疗方法，例如炎症性疾病、炎症性肠病或牛皮癣。
• STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20210015915A1

  公开（公告）日：2021-01-21

  The present disclosure provides novel compounds of Formula (I) below. Compounds of the disclosure act as STING modulators/agonists. The present disclosure further relates to methods of synthesis of compounds of Formula (I) and methods of using of compounds of Formula (I) for the prophylaxis or treatment of cancer and other STING-related diseases. The compounds have the structure represented by Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
• STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20210171565A1

  公开（公告）日：2021-06-10

  The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.